Skip to navigation Skip to content

Systemic light chain amyloidosis (AL) Program in Pharmaceutical Benefits Scheme (PBS) 012-22121931

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised daratumumab for patients with systemic light chain amyloidosis.

For information on how to process a PBS Authority, see Processing Written Authority requests.

Systemic light chain amyloidosis (AL) quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB341 form

 

Written

Electronic

S85:

daratumumab

No

OPA

Must be treated by a:

  • haematologist

Yes

Continuing

Telephone

Electronic

S85:

daratumumab

No

OPA

Must be treated by a:

  • haematologist

Yes